Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel
Primary intracavitary chemoablation with UGN-101 for low-grade upper tract urothelial carcinoma is associated with favorable long-term durability.
Authors
- Alexander Sankin (ORCID: https://orcid.org/0000-0002-8296-4115)
- Ahmad Shabsigh (ORCID: https://orcid.org/0000-0003-1376-4977)
- Michael J. Louie (ORCID: https://orcid.org/0000-0001-5464-8986)
- Nir Kleinmann
- Alon Z. Weizer (ORCID: https://orcid.org/0000-0002-0504-2969)
- Phillip M. Pierorazio (ORCID: https://orcid.org/0000-0003-0766-9981)
- Karim Chamie
- Hristos Z. Kaimakliotis (ORCID: https://orcid.org/0000-0002-0008-9725)
- Andrew Meads (ORCID: https://orcid.org/0000-0002-0847-1005)
- Brian Hu (ORCID: https://orcid.org/0000-0002-7489-9923)
- Mark Schoenberg (ORCID: https://orcid.org/0000-0002-7124-0576)
- Nirmish Singla (ORCID: https://orcid.org/0000-0001-9495-6983)
- Sunil Raju
- Jay D. Raman
- Brent Burger
Institutions
- Albert Einstein College of Medicine (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Loma Linda University (US)
- Sheba Medical Center (IL)
- Mount Sinai Medical Center (US)
- Indiana University School of Medicine
- The Ohio State University (US)
- Indiana University – Purdue University Indianapolis (US)
- University of Pennsylvania (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1097/ju.0000000000004331
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- Bristol-Myers Squibb
- Pfizer
- UroGen Pharma
- Seagen
- Astellas Pharma